LYEL vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LYEL exhibits critical financial weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe deterioration in fundamental health. Despite a speculative 1-year price rally of 178.7%, the company suffers from extreme operating losses (-1,024,633% margin) and negative revenue growth (-45.50%). The valuation is disconnected from fundamentals, evidenced by an astronomical Price/Sales ratio, while insider sentiment remains bearish with consistent selling by top executives.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LYEL vs MRK: Head-to-Head Comparison
This page compares Lyell Immunopharma, Inc. (LYEL) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.